Genmab A/S

Forecast & Rating12 analysts currently cover Genmab A/S, with about 91.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $38.84, about 15.6% upside from the current price of $33.60. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 55.3% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Genmab A/S closely still see room for the stock to rise. Data as of Sep 4, 2026; for reference only and not investment advice.